Rx Medicare

Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today it has established a new collaboration with the National Microbiology Laboratory of the Public Health Agency of Canada and the University of Pennsylvania to further evaluate Inovio DNA vaccine candidates against swine influenza A (H1N1) virus.

Read More…

Related Posts

• Inovio Biomedical Universal Influenza Vaccines Demonstrate 100% Protection Against Current Pandemic A/H1N1 Influenza Viruses In Animal Studies
• Inviragen Researching Vaccines To Protect Against Pandemic And Seasonal Influenza Viruses
• Poor Evidence For Effectiveness Of Influenza Vaccines In Elderly
• Welsh Assembly Government Encourages Parents To Have Children Under Five Vaccinated Against Swine Flu, Wales
• Swine Influenza Daily Update: 24 December 2009, Wales
• Swine Influenza Daily Update: 29 December 2009, Wales
• Swine Influenza Daily Update: 16 December 2009, Wales
• Statement By The Welsh Assembly Government On Latest Developments In Respect Of The Influenza A (H1N1) Swine Flu Pandemic
• Swine Influenza Daily Update: 01 December 2009, Wales
• Swine Influenza Daily Update: 06 December 2009, Wales
• Swine Influenza Daily Update: 24 November 2009, Wales
• SinoFresh Nasal Spray Achieves Positive Results Against H1N1 (Swine Flu) Virus In Initial Pilot Animal Study
• Swine Influenza Daily Update: 09 November 2009, Wales
• NanoViricides, Inc. To Present Anti-Influenza Drug Candidate FluCide™ Studies At The Influenza Congress 2009
• Safety Monitoring Programme Up And Running For Swine Flu Vaccines

Tags: against, biomedical, candidate, efficacy, evaluate, influenza, inovio, laboratory, microbiology, national, pennsylvania, swine, university, vaccines

This entry was posted on Friday, July 3rd, 2009 at 6:07 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.